Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus Camrelizumab and HAIC in Advanced Colorectal Cancer with Liver Metastasis
NCT06423937Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Fudan University. Planned start May 2024; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06423937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423937.